

Cadila Healthcare Limited

Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015. Tel. No. (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com

Unaudited Financial Results for the Quarter ended June 30, 2009.

Rupees in Lacs Except for share data 3 Months Period ended on June 30, 2008 Period ended on June 30, 2008 Period ended on June 30, 2008 Period ended on June 30, 2009 Period e	or share data] Previous accounting Year ended or March 31, 2009 [Audited] 1 173,744 1 3,892 3 169,852 0 24,720 3 194,572 0 1,792 0 1,792 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
3 Months 3 Months Period ended on June 30, 2009 2008 (Unaudited) (Unaudite	Previous accounting Year ended or March 31, 2009 [Audited 4 173,744 1 3,892 8 169,852 0 24,720 0 1,792 6 49,836 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
Sales & Income from operations :	4 173,744 1 3,892 8 169,852 0 24,720 8 194,572 0 1,792 5 49,836 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
Section Sect	1 3,892 3 169,852 0 24,720 3 194,572 0 1,792 5 49,836 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
88,031 68,571 286,240 C C Descriptions 46,527 42,523 2,333 6,509 D Other Income from Operations 13,047 5.5 90,354 71,404 292,749 E Total sales and other income from operations 59,574 48,6527 42,7 (2,619) 2,354 (4,607) A Increase [-] / Decrease [+] in stock in trade & work in progress (259) 3,3 22,065 16,595 66,946 B Consumption of materials 15,817 8,8 8,832 4,819 33,320 C Purchase of traded goods 2,314 4,4 10,246 8,845 35,208 D Employees cost 6,489 5,4 31,457 22,623 101,304 F Other Expenditure 19,256 16,6 72,943 57,694 243,353 G Other Expenditure 19,256 16,6 17,811 13,710 49,396 3 Profit from Operations before Other Income, Interest & Exceptional Items [1-2] 13,860 7, 42,294 1,611 9,778 6 A Interest & financial charges 1,354 1,518 2,270 B Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign	3 169,852 24,720 3 194,572 0 1,792 5 49,836 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
Description Company	24,720 3 194,572 5 49,836 6 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
Total sales and other income from operations Sp,574 48, 48	3 194,572 0 1,792 5 49,836 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
Capta Capt	1,792 49,836 13,350 1 21,803 3 8,256 4 65,763 9 160,800 4 33,772
22,065 16,595 66,946 B Consumption of materials 15,817 8,8 8,832 4,819 33,320 C Purchase of traded goods 2,314 4,4 10,246 8,845 35,208 D Employees cost 6,489 5,4 2,962 2,458 11,182 E Depreciation & Amortisation 2,097 1,4 31,457 22,623 101,304 F Other Expenditure 19,256 16,6 72,943 57,694 243,353 G Total Expenditure 45,714 41,1 17,411 13,710 49,396 3 Other Income Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7,2 422 158 2,036 4 Profit before Interest & Exceptional Items [3 + 4] 15,124 8,2 17,833 13,868 51,432 5 Interest & financial charges 1,518 1,514 1,514 1,514 1,514 1,514 1,518 1,518 1,518 1,518	5 49,836 0 13,350 1 21,803 8 8,256 4 65,763 9 160,800 4 33,772
8,832 4,819 33,320 C Purchase of traded goods 2,314 4,11 10,246 8,845 35,208 D Employees cost 6,489 5,4 2,097 1,1 31,457 22,623 101,304 F Objection & Amortisation 2,097 1,1 31,457 22,623 101,304 F Other Expenditure 19,256 16,4 16,4 19,256 16,4 16,4 19,256 16,4 16,4 19,256 16,4 14,2 11,256 12,24 14,2 13,860 7,2 14,2 158 2,036 4 4 14,264 1,2 13,860 7,2 44,2 158 2,036 4 Other Income Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7,2 14,264 1,2 1,264 1,2 1,264 1,2 1,264 1,2 1,2 1,24 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1	13,350 1 21,803 3 8,256 4 65,763 9 160,800 4 33,772
10,246 8,845 35,208 D Employees cost 6,489 5,4 2,962 2,458 11,182 E Depreciation & Amortisation 2,097 1,4 31,457 22,623 101,304 F Other Expenditure 19,256 16,4 72,943 57,694 243,353 G Total Expenditure 45,714 41, 17,411 13,710 49,396 3 Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7, 422 158 2,036 4 Other Income 1,264 1,244 1,244 1,244 1,244 1,244 1,244 1,244 1,244 1,244 1,254 1,244 1,244 1,244 1,254 1,244	1 21,803 3 8,256 4 65,763 9 160,800 4 33,772
2,962 2,458 11,182 E Depreciation & Amortisation 2,097 1,5 31,457 22,623 101,304 F Other Expenditure 19,256 16,6 72,943 57,694 243,353 G Total Expenditure 45,714 41, 17,411 13,710 49,396 3 Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7, 422 158 2,036 4 Profit before Interest & Exceptional Items [3 + 4] 1,264 1,26	8 8,256 4 65,763 9 160,800 4 33,772
31,457 22,623 101,304 F Other Expenditure 19,256 16,6 72,943 57,694 243,353 G G Total Expenditure 45,714 41,1 17,411 13,710 49,396 3 Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7,2 422 158 2,036 4 Other Income 1,264 1,2 17,833 13,868 51,432 5 Profit before Interest & Exceptional Items [3 + 4] 15,124 8,2 2,294 1,611 9,778 6 A Interest & financial charges 1,354 1,354 1,354 1,354 1,354 1,354 1,354 1,354 1,518 2,2 15,398 10,941 39,384 7 Profit after Interest but before Exceptional Items [5 - 6] 13,606 6,6 15,306 10,941 36,976 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 13,606 6,6 2,424 1,233 6,658 10 Tax expen	4 65,763 9 160,800 4 33,772
72,943 57,694 243,353 G Total Expenditure 45,714 41,13,710 49,396 3 Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7,7 42,24 158 2,036 4 Other Income 1,264	9 160,800 4 33,772
17,411 13,710 49,396 3 Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 13,860 7,2 422 158 2,036 4 Other Income 1,264 <t< td=""><td>33,772</td></t<>	33,772
422 158 2,036 4 Other Income 1,264	
17,833 13,868 51,432 5 Profit before Interest & Exceptional Items [3 + 4] 15,124 8,242 2,294 1,611 9,778 6 A Interest & financial charges 1,354	5,953
2,294 1,611 9,778 6 A Interest & financial charges 1,354 </td <td></td>	
141 1,316 2,270 B Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans 164 9 2,435 2,927 12,048 C Total Financial cost 1,518 2,7 15,398 10,941 39,384 7 Profit after Interest but before Exceptional Items [5 - 6] 13,606 6,0 (92) 0 (2,408) 8 Exceptional Items 0 15,306 10,941 36,976 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 13,606 6,0 2,424 1,233 6,658 10 Tax expense 1,350 9	
2,435 2,927 12,048 C Total Financial cost 1,518 2,7 15,398 10,941 39,384 7 Profit after Interest but before Exceptional Items [5 - 6] 13,606 6,0 (92) 0 (2,408) 8 Exceptional Items 0 15,306 10,941 36,976 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 13,606 6,0 2,424 1,233 6,658 10 Tax expense 1,350 9	-
15,398 10,941 39,384 7 Profit after Interest but before Exceptional Items [5 - 6] 13,606 6,6 (92) 0 (2,408) 8 Exceptional Items 0 15,306 10,941 36,976 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 13,606 6,6 2,424 1,233 6,658 10 Tax expense 1,350 9	
(92) 0 (2,408) 8 Exceptional Items 0 15,306 10,941 36,976 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 13,606 6,0 2,424 1,233 6,658 10 Tax expense 1,350 1.350	
15,306 10,941 36,976 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 13,606 6,0 2,424 1,233 6,658 10 Tax expense 1,350 9	
2,424 1,233 6,658 10 Tax expense 1,350	0 (1,282
12.882 9.708 30.318 11 Net Protit I + 1 / Loss I - I from Ordinary Activities after tax I 9 - 10 I 12.256 5	
	26,591
0 0 0 12 Extraordinary items [net of tax expense] 0 12,882 9,708 30,318 13 Net Profit [+] / Loss [-] for the period [11 - 12] 12,256 5,4	-
(403) (740) (10) 14 Adjustments on consolidation 0	0 0
12,479 8,968 30,308 15 Net Profit [+] / Loss [-] for the period [13 + 14] 12,256 5,	
6,824 6,280 6,824 16 Paid-up equity share capital [Face Value Rs. 5 /-] 6,824 6,380 6,824 6,824	
116,700 17 Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	116,460
18 Earnings Per Share [EPS] [For the period - not Annualised]:	110,100
9.14 6.57* 22.20 A Basic and diluted EPS before Extraordinary items [Rs.] 8.98 4	3* 19.4
9.14 6.57* 22.20 B Basic and diluted EPS after Extraordinary items [Rs.] 8.98 4	
19 Public shareholding:	
34,506,982 35,150,458 34,629,818 - Number of shares 34,506,982 35,150,4	34,629,818
25.28% 27.98% 25.37% - Percentage of Shareholding 25.28% 27.98% 27.98% 25.37% - Percentage of Shareholding	% 25.37%
20 Promoters and Promoter group Shareholding : A Pledged / Encumbered :	
Nil Nil Nil - Number of Shares Nil	lil N
	A. N.A
	A. N.A
B Non-encumbered :	
101,992,031 90,463,250 101,869,195 - Number of Shares 101,992,031 90,463,	1
100% 100% 100% - Percentage of shares [as a % of the total shareholding of promoters and promoter group] 100% 100.0	101,869,195
74.72% 72.02% 74.63% - Percentage of shares [as a % of the total share capital of the company] 74.72% 72.0	

Notes :

- [1] Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website: www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and/or NSE [www.nseindia.com].
- [2] The above results for the quarter ended June 30, 2009 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on July 27, 2009 and the Statutory Auditors of the company have carried out limited review of the financial results of the Company for the quarter ended June 30, 2009
- [3]* Earning per share in item 18 A & B for the 3 months period ended on June 30, 2008 is calculated taking into account the allotment of additional shares issued by the company pursuant to composite scheme of arrangement, to make the figures comparable.
- [4] During the current quarter, the Company has made additional investments in " Zydus BSV Pharma Pvt. Ltd. " amounting to Rs. 95 Lacs.
- [5] The status of investor complaints :
 - Pending at the beginning of the quarter Nil, received and disposed off during the quarter 20, pending at the end of the quarter Nil.
- [6] The Company has one segment of activity viz. " Pharmaceuticals ".
- [7] The standalone figures of Cadila Healthcare Limited for the current quarter are not comparable with the figures of corresponding quarter of previous year because of demerger of Consumer Products Division, which got merged with Zydus Wellness Limited, a subsidiary of Cadila Healthcare Limited.

By Order of the Board, For Cadila Healthcare Limited,

Pankaj R. Patel Chairman & Managing Director